The overall goal of this study is to develop Brillouin microscope as a novel tool for measuring biomechanical and hydration properties of human tissues in vivo.
Healthy volunteers with normal eyes
Visual acuity between +2 to -6 diopters
History of refractive or cataract surgery
History of ocular disease
Active non-ophthalmic systemic disease
Aim 1 - Control Group (Healthy Subjects) : 10 subjects per 6 age ranges (20-29yr, 30-39yr, 40-49yr, 50-59yr, 60-69yr, 70-79yr), total 60 subjects Aim 2 - Patient Groups : 20 patients per 6 diseases (Moderate Fuchs' endothelial dystrophy, Early-stage isolated corneal guttae, Primary open-angle glaucoma, Dry eye disease, Keratoconus, post-LASIK), total 120 patients.
Cohort
Retrospective
Not listed
Number of subjects to successfully complete Brillouin measurement without serious unanticipated adverse events related to application of the device.
Number and percentage of enrolled subjects who complete the single Brillouin imaging session without experiencing a serious unanticipated adverse event related to the investigational Brillouin Ocular Scanner, as determined by study staff monitoring during and immediately following the imaging procedure.
Click on the lead sponsor to view all of their trials.
Massachusetts General Hospital
Lead sponsor
Massachusetts Eye and Ear Infirmary
Collaborator
National Eye Institute (NEI)
Collaborator
